Producing trustworthy evidence is challenging. What are the best solutions for producing evidence best suited to important health priorities? These solutions might focus on methods, tools, processes and relationships. These should aim to promote rapid, relevant and trusted evidence production.

We are interested in work that builds capacity in evidence production right now, that integrates new technologies, repositories, methods and data sharing to strengthen evidence production for the future.

Advocating for conditions that best support the production of trusted evidence, including work on research transparency and data sharing, fraud in research, avoiding duplication of effort and research waste, and building capacity for evidence generation in all contexts.

This stream is about building on our ability to share uncertainties and the evolving nature of evidence, generating trust in evidence and countering misinformation. This includes - but is not limited to - how we engage with evidence users to understand what they need to support their health decision making and how we make trustworthy information valuable and useable.

Working in partnership helps build trust in the evidence we produce. Partnership working can include prioritizing the needs of evidence users and ensuring that evidence addresses priority questions that are important to them.

At a systems level, we need to consider connecting primary and secondary research, including bringing together those making health decisions at all stages of evidence production and sharing.

• Abstracts must be submitted online by 6 March 2023 (23:59 GMT).
• Only abstracts submitted in English will be considered.
• Abstracts must not be more than 350 words.
• The abstract should follow the structure: Background, Objectives, Methods, Results, Conclusions. If your abstract does not fit into this format, please choose appropriate headings. Please include a statement on the relevance and importance to patients. This may be of direct relevance or it may be as a contribution to methods that result in more robust evidence production.
• The abstract title should not be longer than 20 words.
• Abbreviated terms should be written in full the first time they are used.
• Tables and graphs can be submitted as an attached image document with your abstract. Allowed formats are: gif, png, jpg, jpeg, tif, tiff, pdf. Please remember to insert the reference (Table 1, Figure 1, etc.) in the abstract.
• You do not need to submit a PDF version of the abstract alongside the form.

You will receive an automated email acknowledging your abstract submission. (Please allow up to 20 minutes to receive this email). If you do not receive an email, or if you require any help with submitting your abstract, please email abstracts@cochrane.org.

Acceptance of abstracts into the conference programme will be determined by the scientific merit,  relevance, readability and clarity, and learning potential of the submitted work.   Abstracts may be evaluated by at least one patient or healthcare consumer partner, so keep that in mind when submitting.

At the time of submission, you will be asked to indicate a preference for oral or poster presentation; however, the final decision on the type of presentation offered is made by the Abstract Committee. We aim to notify authors of acceptance or rejection of their submission by 24 April 2023.

All presenters of accepted abstracts are required to register and attend the conference. The organizers reserve the right to withdraw abstracts if presenters have not registered for the London Colloquium by 2 June 2023.